Lack of Guidelines Create Need for Novel Options for Vulvar/Vaginal Melanoma
Source: Targeted Oncology, February 2022
In an interview with Targeted Oncology, Annelise Wilhite, MD, discussed the findings of a clinical investigation of survival in patients with vulvar/vaginal melanomas.
Treatment options for vulvar/vaginal melanoma tend to mimic those of cutaneous melanoma due the lack of specific therapy guidelines put into place. Understanding the differences between those 2 diseases is crucial in understanding on how that difference affects therapy.
Because of the rarity of the disease, a study examined patients with vulvar/vaginal melanoma as they were treated with immunotherapeutic agents including pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy).